Issue 94, 2012

Prussian blue nanoparticles operate as a new generation of photothermal ablation agents for cancer therapy

Abstract

Herein, prussian blue nanoparticles, an ancient dye, were explored as a new generation of near-infrared laser-driven photothermal ablation agents for cancer therapy alternative to traditional agents due to their good photothermal efficiency and high photothermal stability but low cost and particularly clinically approved biosafety.

Graphical abstract: Prussian blue nanoparticles operate as a new generation of photothermal ablation agents for cancer therapy

Supplementary files

Article information

Article type
Communication
Submitted
04 Sep 2012
Accepted
12 Oct 2012
First published
18 Oct 2012

Chem. Commun., 2012,48, 11567-11569

Prussian blue nanoparticles operate as a new generation of photothermal ablation agents for cancer therapy

G. Fu, W. Liu, S. Feng and X. Yue, Chem. Commun., 2012, 48, 11567 DOI: 10.1039/C2CC36456E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements